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Introduction
Gallbladder cancer (GBC) is considered to be a rare
malignancy in the west  but its incidence and prevalence
is  high in South-East Asia (Rizvi and Zuberi 2003; Batra
et al., 2005; Rand et al., 2006). Unfortunately no tumor
registry exists in Pakistan, sporadic hospital based studies
and data from Karachi cancer registry suggest that GBC
is common malignancy in Pakistan especially in females.
In a study conducted by Bhurgri et al it was 3rd most
common malignancy in females and ninth common cancer
overall in Karachi south (Bhurgri et al., 2002). GBC was
found to be the second most common malignancy in
females , in a hospital based cancer registry (Zahir et al.,
2000).
GBC is more common in females and gallstones are
considered to be number one risk factor for this
malignancy. Other associated risk factors are obesity,
female sex, high number of pregnancies and age at first
child, family history, anomalous pancreaticobiliary ductal
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Abstract
Background: Gall bladder cancer (GBC) is a common malignancy in our country; very limited data exist on
this malignancy in Pakistan. Methods: This is a retrospective analysis of all the admitted patients diagnosed
with GBC or cholangiocarcinoma in between 1st January 1995 to 31st December 2007. Results: A total of 245
patients were admitted with diagnosis of GBC or cholangiocarcinoma. Sixty seven percent were females. Right
hypochondrial pain (70.6%) and jaundice (49.8%) were the commonest symptoms, followed by nausea and
vomiting (11.8%), weight loss (13%), fever (18.8%), anorexia (9.8%) and ascites (3.3%). Gall stones were seen
in 132 (53.9%) patients. Pathological diagnosis was confirmed in 155 (63.2%) patients, adenocarcinoma (94.83%)
being the predominant type. Metastasis was seen in 204 (83.3%) patients, with liver and abdominal lymph nodes
being the frequent sites of metastasis. Most of the patients presented to the surgeons (42.9%) and
gastroenterologists (35.9%) at their first visit. Only 89 (26.3%) patients were referred to medical oncologists
and 42 (16.7%) of the patients actually received chemotherapy. The patients who received chemotherapy cisplatin
and gemcitabine demonstrated partial responses (40%). Common bile duct stricture was seen in 78 patients and
stenting was successful in 73 patients. Fourteen (5.7%) patients are alive to date, one is receiving chemotherapy,
and another is alive with advanced disease while 10 patients had incidental diagnosis after surgery. Of all 53.9%
of patients have died and 38% are lost to follow up. Conclusion: Most of the patients with biliary cancers
present late with advanced disease at our referral tertiary care hospital. Minority of the patients received
chemotherapy and most of responses were observed with cisplatin and gemcitabine combination or capecitbine
based therapy.
Key Words:  Gallbladder cancer - symptoms - clinical details
junction and chronic infections with Salmonella typhi and
S. paratyphi and Helicobacter pylori and H. bilis (de
Groen et al., 1999; Rizvi and Zuberi, 2003; Batra et al.,
2005; Randi et al., 2006).
Our hospital is a leading tertiary care facility of the
area and patients not only from across the Pakistan but
from Afghanistan, Iran and United Arab Emirates come
to this centre for the treatment of different diseases,
malignant or nonmalignant. Keeping in view the
prevalence of the GBC in our country we decided to assess
our data of patients who were diagnosed with biliary
cancers.
Materials and Methods
This is a retrospective analysis of all patients who were
diagnosed to have biliary cancers during last 12 years from
1st January 1995 to 31st December 2007. Case records
were reviewed and data was entered in a self made well
structured  performa  regarding age, gender, symptoms at
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presentation, association of gallstones, mode of diagnoses
(radiological or pathological), stage at presentation,
treatment offered, palliative procedure undertaken.
Patients who were lost to follow-up were called on phone
if possible. The data was analyzed using SPSS V 16.
Results
A total of 245 patients were diagnosed to have biliary
cancer during this period. GBC was diagnosed in 214
(87.3%) and cholangiocarcinoma in 29 (11.8%) patients.
Mean age at presentation was 57.7 years (range 30-86
years) and 165 (67.3%) were females while 80 (32.7%)
patients were male with female to male ratio of 2:1.
Clinical Features
Right upper quadrant pain was found to be the
commonest presenting  symptom, seen in   173 (70.6%)
patients followed by jaundice in 122 (49.8%) patients.
Other symptoms noticed at presentation were fever,
perhaps secondary to cholangitis 46 (18.8%), weight loss
32 (13.1%), nausea and vomiting 29 (11.8%), anorexia
24 (9.8%) and ascites in 8 (3.3%) patients.
Imaging studies
Ultrasound and CT scan were used as imaging
modalities to assess the disease status and in fact in 90
(36.7%) patients, a diagnosis was made only on
radiological findings. The main radiological finding was
gallbladder mass. Gallstones were visible in 132 (53.9%)
patients.
Pathology
Histopathological confirmation of cancer was obtained
in 155 (63.3%) patients. Adenocarcinoma was the most
common pathological type found in 147 (94.83%) patients.
Other pathologies seen were squamous cell carcinoma 4
(2.58%), neuroendocrine tumor 3 (1.93%) one patient had
a positive cytology of ascetic fluid (0.64%). Pathological
grading was available in only 59 patients. In 13 (22.03%)
patients tumor was well differentiated while in 26
(44.06%) and 18 (30.5%) patients tumor was moderately
differentiated and poorly differentiated respectively while
in 2 (3.38%) patients it was undifferentiated (Table 1).
Stage at presentation
All but 41 (16.7%) patients presented with the
metastatic disease. Liver was the commonest site of
metastasis. In 77 (31.4%) liver was the only site of
metastasis, in other 77 (31.4%) patients liver and regional
lymph nodes were involved by the disease, 10 (4.1%)
patients had  liver and gut metastasis and in 7 (2.9%)
patients liver was involved by the disease along with the
lung and regional lymph nodes. Other sites of metastatic
disease are shown in Table 1.
Interventions/Procedures
Most of the patients required some sort of intervention
for diagnoses or as palliative procedure. In 37 (15.1%)
patients a biopsy was done under CT scan or ultrasound
guidance, 44 (21.9%) required endoscopic retrograde
cholangiopancreatoscopy (ERCP), 39 (15.9%) patients
required percutanous transhepatic cholangiography (PTC),
palliative surgery was performed in 66 (26.9%) patients,
laproscopic/open cholecystectomy was done on 10 (4.1%)
patients. To relieve obstruction stenting of common bile
duct was performed in 73 (29.8%) patients, with ERCP in
34 (13.9%) and with PTC in 39 (15.9%) patients. In 1
patient en bloc resection of the tumor and involved liver
was carried out.
Patient’s first encounter and referrals
Surgeons were to see the most of patients at their initial
presentation, to whom 105 (42.9%) patients made their
first visit, followed by gastroenterologists 88 (35.9%) and
general physicians 27 (11%). Of all 89 (36.3%) patients
were referred to the medical oncologist while in 120 (49%)
patients no referral was suggested. Rest of the patients
were referred to the surgeons 8 (3.3%), gastroenterologists
22 (9%) for interventional or palliative procedures.
Chemotherapy
Of 88 (36.3%) patients seen by the medical oncologists
42 (47.19%) patients were offered chemotherapy and 1
out of those 42 patients refused to take chemotherapy. In
remaining 41 patients different chemotherapeutic agents
were used. Cisplatin and gemcitabine as combination
therapy was used in 13 (31.7%) patients, capecitabine as
single agent in 10 (24.4%) patients, flourouracil with
leucovorin in 15 (36.6%) patients, gemcitabine as single
agent in 2 (4.9%), etoposide with cisplatin in 2 (4.9%)
and gemcitabine with flouorouracil were used in 1 (2.4%)
patient. Out of all these, better responses were witnessed
with either gemcitbine and cisplatin or capecitbine. All
responses were partial responses (53.8% with gemcitabine
and cisplatin and 40% with capecitabine) while rest of
the chemotherpeutic agents did not show objective clinical
Table 1. Pathology, Type, Grade, Size (T) and
Metastasis Sites
Pathological Diagnosis 155 (63.3%)
Adenocarcinoma 147 (94.8%)
Squamous cell cancer 4  (2.6%)
Neuroendocrine cancer 3  (1.9%)
Ascitic Cytology 1  (0.6%)
Radiological Diagnosis 90 (36.7%)
Grade 59
Well Differentiated 13 (22.0%)
Moderately Differentiated 26 (44.1%)
Poorly differentiated 18 (30.5%)
Undifferentiated 2 (3.38%)
Site of metastasis
Liver only 77 (31.4%)
Liver and Lymph nodes 77 (31.4%)
Serosal surface of Gut 13  (5.3%)
Liver and Gut 10  (4.1%)
Lymph nodes 10  (4.1%)
Lung 7  (2.9%)
Liver + Lungs + Lymph nodes 7  (2.9%)
Diaphragm 1  (0.4%)
Adrenal gland 1  (0.4%)
Bone 1  (0.4%)
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response. With continuous therapy all patient noticed
progressive disease after some time except one whose
disease remain stable after 10 months of treatment.
All types of chemotherapy were tolerated fairly well
especially gemcitbine and cisplatin in combination or
capecitabine as a single agent.
One patient who was subjected to enbloc resection of
gall bladder mass along with involved liver and hepatic
flexure of colon later received concurrent radiation with
5-Flourouracil and Leucovorin followed by 4 more cycles
of same chemotherapy remain free of disease for 11
months and now being treated with gemcitabine and
cisplatin after recurrence in the abdominal wall and mass
along the duodenum.
Survival
Of all 245 patients only 14 (5.7%) patients are alive
till today, 132 (53.9%) patients have died while 99 (40.4%)
patients have lost to follow up and we do not have
information for these patients. Of surviving 14 patients,
an incidental diagnosis of gallbladder cancer was made
in 10 patients after laproscopic/open cholecystectomy
while remaining 4 patients are alive with the disease and
one patient is receiving chemotherapy after recurrence of
the disease. Median survival observed with gemcitabine
and cisplatine combination was 3.3 months while with
capecitabine it was 2.4 months.
Discussion
GBC along with cholangiocarcinoma carry a grim
prognosis and usually are diagnosed at late stages
Established factors are  chronic infections/inflammatory
conditions, gallstones, female gender, obesity, congenital
anomalies of hepatobiliary tract, molecular/genetic
defects, family history and multiple pregnancies (Nawaz
2000; Kapoor and McMichael, 2003; Rizvi and Zuberi,
2003; Barakat et al., 2006; Kumar et al., 2006; Randi et
al., 2006; Roa et al., 2006).
Here we have reported the 13 years of experience of
biliary cancer at our hospital. Most common symptoms
at presentation were right upper quadrant pain in 70.6%
patients and jaundice in 49.8% patients and these findings
are similar to the local, regional as well as international
literature (Chih Jung Shieh 1981; Shukla et al., 1985;
Nawaz, 2000; Batra et al., 2005; Malik, 2006). Batra et
al(2005) have reported that 81% of patients in their study
had upper quadrant abdominal pain and 73% had jaundice
at presentation while in series reported by Nawaz et al
(2000) 90% patients presented with upper abdominal pain
and 60% had jaundice.
The mean age at the presentation in our study seems
to be different only for female population (57 years) which
is higher than mean age observed in other studies from
Pakistan (Nawaz, 2000; Zahir et al., 2000; Rizvi and
Zuberi, 2003) and India (Shukla et al. 1985; Batra et al.,
2005) but younger than the western population (Chih Jung
Shieh, 1981). The gender distribution found in our study
however matches the literature published from our region
as well as from west (ratio 2:1 ) (Chih Jung Shieh, 1981;
Shukla et al., 1985; Nawaz, 2000; Zahir et al., 2000; Rizvi
and Zuberi, 2003; Batra et al., 2005).
Due to non specificity of symptoms most patients get
diagnosed at advanced stage of the disease when less is
left to offer and majority of patients end up having
palliative treatment. In our study we observed that 83.3%
patients presented when disease was already metastatic.
Liver was the common site of metastasis. Other affected
sites were regional lymph nodes, lungs, serosal surface
of the gut, diaphragm, adrenal gland and bone. Our
findings are almost similar to the findings of Batra et al
(2005) and Shukla et al (1985).
Pathological confirmation of GBC is not necessary
for the diagnosis, clear radiological appearance along with
suggestive  symptoms are usually all that is required for
making a diagnosis, Pathology is however required in
patients with suspicion of malignancy without typical
radiological findings and / or absence of symptoms. In
our study population 63.3 % patients had to undergo
procedures for pathological diagnosis. Pathological
diagnosis was confirmed in 155 (63.3%) patients while
in 90 (36.7%) radiological findings were suggestive of
the gall bladder cancer and due to advanced nature of the
disease and poor performance status of all these patients,
no intervention was done to confirm pathological
diagnosis. Among 155 patients in whom pathological
diagnosis was confirmed, adenocarcinoma was the most
common histological type found in 147 (94.83%) patients.
Gall stones are believed to be associated with
development of gallbladder cancer.  This association has
been also found in other studies as well (Chih Jung Shieh
1981; Kapoor and McMichael, 2003; Rizvi and Zuberi,
2003; Batra et al., 2005). In our study 53.9% patients were
found to have gall stones, a common association of this
disease and considered to be a risk factor for the
development of gall bladder cancer.
Majority of patients required some intervention, either
for the diagnosis, treatment or for palliation.  In 10 (4%)
patients diagnosis of GBC was made after
cholecystectomy (laproscopic/open) performed due to gall
stone associated acute cholecystitis and all of them had
disease at earlier stage. Incidental GBC finding after
cholecystectomy is well reported in literature and is in
range from 1% to 2%, but in different series 2 to 10%
patients were found to have incidental GBC (Batra et al.,
2005). Survival for patients with incidental diagnosis of
GBC is generally good as disease is usually found at earlier
stages, and after median follow-up of more than 60 months
all of these patients are alive without disease recurrence.
One patient subjected to enbloc resection of gall
bladder mass invading the liver and hepatic flexure of
colon with resection of regional lymph nodes. To relieve
the obstruction stenting of the common bile duct or hepatic
ducts was carried out in 29.8% patients. In 26.93%
patients, some kind of palliative surgery was done.
Most of the patients were entertained by general
surgeons or gastroenterologists while 89 (36.3%) patients
were referred to the medical oncologists and out of those
42 patients were offered chemotherapy among which 1
patient refused to take the chemotherapy while remaining
41 (46.06%) patients received chemotherapy with
different agents. Patients treated with 5-flourouracil did
Shiyam Kumar et al
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